Picture Berlin Partner Hotspot for Startups 650x80px
Document › Details

Nordic Nanovector ASA. (6/1/18). "Press Release: Nordic Nanovector Strengthens Management Team with Appointment of Maureen Deehan, PhD, as Head of Corporate Development and Strategy". Oslo.

Organisations Organisation Nordic Nanovector ASA (OSE: NANOV)
  Group Nordic Nanovector (Group)
  Organisation 2 Novimmune S.A.
Products Product Betalutin®
  Product 2 drug development
Persons Person Deehan, Maureen (Nordic Nanovector 201806– Head Corp Developm + Strategy before Novimmune + Grünenthal UK + Oraganon)
  Person 2 Renoldi, Marco (Nordic Nanovector 201806 COO)

Nordic Nanovector ASA (OSE: NANO) announces that Maureen Deehan, PhD, has been appointed as Head of Corporate Development and Strategy. Maureen will work alongside Chief Operating Officer Marco Renoldi on the development and execution of the Company’s corporate development strategy.

Maureen has 25 years’ experience in business development, clinical development and translational biology. Prior to her appointment, Maureen served for seven years at Novimmune, a Swiss biotech company developing antibody-based drugs for the treatment of inflammatory diseases, immune-related disorders and cancer. Her most recent role there was as Director of Business Development & Alliance Management, prior to which she held other positions, including Business Development & Scientific Licensing Lead, Section Head of Translational Research & Alliance Management, and Head of Pharmacology.

Before joining Novimmune, Maureen served as Medical Science Liaison Manager at Grünenthal UK and as Team Leader of the Department of Molecular Pharmacology at Organon Laboratories.

Maureen has a PhD from the Faculty of Medicine, University of Glasgow and a BSc in Biochemistry & Pharmacology from the University of Strathclyde.

Marco Renoldi, Chief Operating Officer of Nordic Nanovector, commented: “It is with great pleasure that we welcome Maureen to the team. Her core scientific expertise in targeted therapies, based on antibodies and related technologies, combined with a successful track record in business development and deal-making are an extremely important addition to Nordic Nanovector.”

Maureen Deehan added: “I am pleased to be joining Nordic Nanovector at this important time for the Company as it advances Betalutin® through clinical development for non-Hodgkin’s lymphoma. I look forward to evaluating relevant strategic opportunities and working to further build the Company’s business development network.”

For further information, please contact:

IR enquiries
Malene Brondberg, VP, Investor Relations and Corporate Communications
Tel/Cell: + 44 7561 431 762

International Media Enquiries
Mark Swallow/David Dible/Isabelle Andrews (Citigate Dewe Rogerson)
Tel: +44 207 638 9571

About Nordic Nanovector

Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers.

Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a novel CD37-targeting antibody-radionuclide-conjugate designed to advance the treatment of non-Hodgkin's lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 20 billion by 2024. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets.

Further information can be found at

Record changed: 2018-08-04


Picture [iito] Plain Stupid Simple 650x80px

More documents for Nordic Nanovector (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture Demy-Colton BioFuture 2021 NYC B Preview Download 650x300px

» top